Biomedical Engineering Reference
In-Depth Information
Desiraju R, Chintagunta P, Balasubramaniam SK, Johnson G (2004a) Spillover of direct-
to-consumer prescription drug advertising to Canada. Working Paper
Desiraju R, Nair H, Chintagunta P (2004b) Diffusion of new pharmaceutical drugs in developing
and developed nations. Int J Res Mark 21(4):341-357
DiMasi J, Hansen R, Grabowski H (2003) The price of innovation: new estimates of drug develop-
ment costs. J Health Econ 22:151-185
Ding M, Eliashberg J (2008) A dynamic competitive forecasting model incorporating dyadic decision
making. Manage Sci 54(4):820-834
Erdem T (1998) An empirical analysis of umbrella branding. J Mark Res 35:339-351
Erdem T, Sun B (2002) An empirical investigation of the spillover effects of advertising and sales
promotions in umbrella branding. J Mark Res 39(4):408-420
Erickson G (1992) Empirical analysis of closed-loop duopoly advertising strategies. Manage Sci
38:1732-1749
Feldman JM, Lynch JG Jr (1988) Self-generated validity and other effects of measurement on
belief, attitude, intention, and behavior. J Appl Psychol 73(3):421-435
Fischer M, Albers S (2010) Patient- or physician-oriented marketing: what drives primary demand
for prescription drugs. J Mark Res 47:103-121
Frank R, Salkever D (1992) Pricing, patent loss and the market for pharmaceuticals. South Econ J
59(2):165-179
Gruenspecht HK, Lave LB (1989) The economics of health, safety, and environmental regulation.
In: Schmalensee R, Willig RD (eds) Handbook of industrial organization, vol II. Elsevier,
Amsterdam
Hakenes H, Peitz M (2008) Umbrella branding and the provision of quality. Int J Ind Organ
26(2):546-556
Howard T (1996) McDisney' alliance shows brute force with Dalmatians' tie-in. Nation's
Restaurant News
Iyer G (1998) Coordinating channels under price and nonprice competition. Mark Sci 17(4):338-355
Janakiraman R, Sismeiro C, Dutta S (2009) Perception spillovers across competing brands: a
disaggregate model of how and when. J Mark Res 46:467-481
Kaiser J (2012) New cystic fibrosis drug offers hope, at a price. Science 335(10):645
Kravitz R, Epstein R, Feldman M, Franz C, Azari R, Wilkes M, Hinton L, Franks P (2005)
Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized
controlled trial. J Am Med Assoc 293(16):1995-2002
Kremer S, Bijmolt T, Leeflang P, Wieringa J (2008) Generalizations on the effectiveness of
pharmaceutical promotional expenditures. Int J Res Mark 25:234-246
Kumar P (2005) Brand counterextensions: the impact of brand extension success versus failure.
J Mark Res 42:183-194
Lal R (1990) Improving channel coordination through franchising. Mark Sci 9(4):299-318
Lei J, Dawar N, Lemmink J (2008) Negative spillover in brand portfolios: exploring the antecedents
of asymmetric effects. J Mark 72:111-123
Lilien GL, Kotler P, Sridhar Moorthy K (1992) Marketing models. Prentice Hall, Englewood
Cliffs, NJ
Ling DC, Berndt ER, Kyle MK (2002) Deregulating direct-to-consumer marketing of prescription
drugs: effects on prescription and over-the-counter product sales. J Law Econ XLV:691-723
Mantrala MK, Sinha P, Zoltners AA (1992) Impact of resource allocation rules on marketing
investment-level decisions and profitability. J Mark Res 29:162-175
Mas-Colell A, Whinston MD, Green JR (1995) Microeconomic theory. Oxford University Press,
Oxford, NY
Mintzes B, Barer ML, Bassett K, Kazanjian A, Evans RG (2001) An assessment of the health
system impacts of direct to consumer advertising of prescription medicines. Working Paper
HPRU 02:3D, Centre for Health Services and Policy Research, University of British Columbia,
Aug
Mizik N, Jacobson R (2004) Are physicians “easy marks”? Quantifying the effects of detailing and
sampling on new prescriptions. Manage Sci 50(12):1704-1715
Search WWH ::
Custom Search